February 14, 2012; 78 (7) Articles
Fatal PML associated with efalizumab therapy
Insights into integrin αLβ2 in JC virus control
N. Schwab, J.C. Ulzheimer, R.J. Fox, T. Schneider-Hohendorf, B.C. Kieseier, C.M. Monoranu, S.M. Staugaitis, W. Welch, S. Jilek, R.A. Du Pasquier, W. Brück, K.V. Toyka, R.M. Ransohoff, H. Wiendl
First published February 1, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182478d4b
N. Schwab
J.C. Ulzheimer
R.J. Fox
T. Schneider-Hohendorf
B.C. Kieseier
C.M. Monoranu
S.M. Staugaitis
W. Welch
S. Jilek
R.A. Du Pasquier
W. Brück
K.V. Toyka
R.M. Ransohoff
Fatal PML associated with efalizumab therapy
Insights into integrin αLβ2 in JC virus control
N. Schwab, J.C. Ulzheimer, R.J. Fox, T. Schneider-Hohendorf, B.C. Kieseier, C.M. Monoranu, S.M. Staugaitis, W. Welch, S. Jilek, R.A. Du Pasquier, W. Brück, K.V. Toyka, R.M. Ransohoff, H. Wiendl
Neurology Feb 2012, 78 (7) 458-467; DOI: 10.1212/WNL.0b013e3182478d4b
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 78 no. 7 458-467
PubMed:
Print ISSN:
Online ISSN:
History:
- Received January 19, 2011
- Accepted July 6, 2011
- First Published February 1, 2012.
Article Versions
- Previous version (February 1, 2012 - 13:03).
- You are viewing the most recent version of this article.
Copyright & Usage:
Copyright © 2012 by AAN Enterprises, Inc.
Author Disclosures
- N. Schwab, PhD,
- J.C. Ulzheimer, MD,
- R.J. Fox, MD,
- T. Schneider-Hohendorf, MSc,
- B.C. Kieseier, MD,
- C.M. Monoranu, MD,
- S.M. Staugaitis, MD, PhD,
- W. Welch, MD,
- S. Jilek, PhD,
- R.A. Du Pasquier, MD,
- W. Brück, MD,
- K.V. Toyka, MD,
- R.M. Ransohoff, MD* and
- H. Wiendl, MD*
- N. Schwab, PhD,
- J.C. Ulzheimer, MD,
- R.J. Fox, MD,
- T. Schneider-Hohendorf, MSc,
- B.C. Kieseier, MD,
- C.M. Monoranu, MD,
- S.M. Staugaitis, MD, PhD,
- W. Welch, MD,
- S. Jilek, PhD,
- R.A. Du Pasquier, MD,
- W. Brück, MD,
- K.V. Toyka, MD,
- R.M. Ransohoff, MD* and
- H. Wiendl, MD*
- From the Department of Neurology–Department of Inflammatory Diseases of the Nervous System and Neurooncology (N.S., T.S.-H., H.W.), University of Münster, Germany; Department of Neurology (N.S., J.C.U., T.S.-H., K.V.T., H.W.) and Department of Pathology, Division of Neuropathology (C.M.M.), University of Würzburg, Germany; Neurological Clinic (J.C.U.), Bad Mergentheim, Germany; Mellen Center for Multiple Sclerosis, Neurological Institute (R.J.F., R.M.R.), Departments of Neurosciences and Anatomic Pathology (S.M.S.), and Neuroinflammation Research Center, Lerner Research Institute (R.M.R.), Cleveland Clinic Foundation, Cleveland, OH; Department of Neurology (B.C.K.), University of Düsseldorf, Germany; Topeka Neurology Associates (W.W.), Topeka, KS; Divisions of Immunology and Allergy and of Neurology (S.J., R.A.D.), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and Institute of Neuropathology (W.B.), University of Göttingen, Germany.
- Correspondence & reprint requests to Prof. Wiendl: heinz.wiendl{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosisClemens Warnke, Anne K. Mausberg, Mark Stettner et al.Neurology, September 18, 2013 -
Editorial
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve et al.Neurology, September 18, 2013 -
Article
l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz et al.Neurology, August 07, 2013 -
Article
Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathyEvelyn Dubois, Christoph Ruschil, Felix Bischof et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2015